INTRODUCTION
Female sexual dysfunction (FSD) includes a wide range of common disorders such as hypoactive sexual desire, poor sensation, vasocongestion, lubrication, sexual pain, and inability to achieve orgasm/satisfaction [1] . Sexual dysfunction occurs in 40-45% of women and 20-30% of men at least once in their lifetime [2] .
FSD can be treated by hormonal therapy such as estrogen, progesterone, and testosterone and others like the phosphodiesterase type 5 inhibitors, dopaminergic agonists, and prostaglandins [3] .
Sildenafil citrate is among the phosphodiesterase type 5 inhibitors that improve FSD through increasing blood flow to corpus cavernosum of clitoris, vagina, and labia minor [4] .
Because there is a controversy about treatment of FSD, we aim in this study to evaluate the effect of sildenafil citrate in the treatment of FSD.
MATERIALS AND METHODS
A quasi-experimental pre-post-test single group design of 43 women complaining of sexual dysfunction was established from November 2015 till June 2017. Patients in a stable, heterosexual relationship with normal hormonal profile and normal sexual function of male partner by using the international index of erectile function-5 were included.
Women with a history of hypertension and on antihypertensive treatment, those with coronary heart disease or on treatment with vasodilator such as nitrates and α-blocker, those with impaired hepatic function, and those who were taking any medication such as antidepressant and antipsychotic drugs were excluded.
Each patient completed the 19-item FSFI questionnaire at the begining of the study and at the end of study after 6 weeks of taking sildenafile citrate 25 mg daily on empty stomach. A score up to 26.5 is classified as FSD.
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Ethical approval:
Approval from the Institutional Ethics and Research Committee of Faculty of Medicine, South Valley University, Egypt, was obtained. Moreover, informed written consent was obtained from each woman before enrollment in the study.
Analysis of data was done by IBM computer using statistical program for social sciences (SPSS Inc., Chicago, ILUSA, version 20) as follows: description of quantitative variables as mean, SD, and range, and description of qualitative variables as number and percentage. Paired t-test was used to compare the difference in means between the two groups, and correlation coefficient test (r) was used to rank variables against each other either positively or inversely. Correlation is significant at the 0.05 level (two tailed) based on normal approximation.
RESULTS
Our study was performed on 43 women complaining of sexual dysfunction with a mean of age 30.5 ± 6.4 years old. Overall, 37.2% of the women in our study had firstdegree circumcision and 62.8% were had second-degree circumcision.
At the start of this study, 100% of participants had been complaining of FSD with score less than 26.5 of FSFI questionnaire, whereas after completing 6 weeks of treatment, 34.4% of women became normal and had a score more than 26.5 on FSFI questionnaire, but 65.6% of the women still had FSD, as they had scores less than 26.5 on FSFI. At the end of the study, 11 woman not able to complete the study and missed the follow-up.
The six female sexual domains and the total FSFI score were compared before and after treatment with sildenafil 25 mg daily for 6 weeks. There was a statistically significant improvement in all female sexual domains in FSFI and in total FSFI score (P<0.001). Improvement in the domains ranged as follow: orgasm 69% is the best followed by desire 68%, lubrication 64%, arousal 48%, satisfaction 42% and pain 21%, whereas the total score improvement by 41% (Table 1 ).
We also found that there was a statistically significant (P<0.001) improvement of percentage after treatment of first-versus second-degree circumcision in desire, lubrication, orgasm domains, and total score ( Table 2 ). 
DISCUSSION
In the current study, we found that the treatment of patients with FSD by sildenafil citrate 25 mg daily for 6 weeks had significant improvement effect on all domains of FSD, with no improvement in pain score, and was more effective in the first-degree circumcised women than second-degree circumcised women according to FSFI questionnaire.
Nurnberg et al. [5] showed an improvement in orgasmic functioning and sexual arousal with sildenafil in female patients on selective serotonin re-uptake inhibitors.
Nurnberg et al. [6] found that the women receiving sildenafil had significantly greater improvements in sexual function than those who had taken placebo.
Berman et al. [7] had demonstrated significant increases in satisfaction, subjective desire, arousal, and lubrication after 6 weeks of sildenafil 100 mg administration as assessed by questionnaire.
Caruso et al. [8] [9] [10] showed a significant improvement in all aspects of FSD, including desire, arousal, lubrication, satisfaction, orgasm, and dyspareunia when use sildenafil 25 mg.
On contrary, Kaplan et al. [11] found that sildenafil citrate was safe but less effective in FSD, although there were changes in vaginal lubrication and clitoral sensitivity.
Basson et al. [12] showed that there was no improvement in sexual response with multiple doses of sildenafil in a large randomized, placebo controlled, double-blind study in 781 estrogenized and estrogen-deficient postmenopausal women with female sexual arousal disorder who had received 10, 50, or 100 mg of sildenafil or placebo.
Basson and Brotto [13] conducted a randomized, doubleblind and placebo-controlled study on 34 estrogenized postmenopausal women with acquired genital female sexual arousal disorder and impaired orgasm. Sildenafil did not improve either orgasm or arousal in those patients.
Alexander et al. [14] found a nonsignificant difference between sildenafil versus placebo in successful sexual activities at the end of treatment versus baseline.
Therefore, further studies are needed to evaluate the effects of sildenafil citrate on FSD.
CONCLUSION
Sildenafil may improve all domains of FSD, mainly affecting desire, orgasm, and lubrication. However, further studies on a bigger sample of patients is needed to confirm our findings.
